In HUVEC, 72 h proliferation IC50 values were 0.17 μM with VEGF and 23.4 μM with FBS stimulation, demonstrating strong dependence on assay context. [1]
In primary epithelioid peritoneal mesothelioma cells, apatinib did not produce detectable apoptotic nuclear changes or increased caspase activity after 24 h under the tested conditions. This negative result is model- and endpoint-specific. [2]
Cell-free kinase inhibition panel
Biochemical assay · Isolated tyrosine kinases; sunitinib comparator [1]
VEGFR-2 inhibition was strongest among the tested kinases; selectivity was relative, not absolute.
Literature-Reported Treatment Conditions
- Method
- ELISA kinase assay; Logit IC50 from three independent experiments
- Reported limits
- ATP concentration and exposure duration are not specified in the retrieved assay paragraph; no kinetic binding claim is made.
Methods and source locations
Compound reported in the paper: Apatinib mesylate; Compound label in the paper: YN968D1
Published material and model only; no verification of the A11407 lot or salt conversion.
Table 3; Methods: Enzyme-linked immunosorbent assay; Results: Inhibition of tyrosine kinase activities
VEGFR-2 kinase activity: ELISA; three independent experiments — Table 3; Enzyme-linked immunosorbent assay
Other kinase activities: ELISA — Table 3
Stimulus-dependent endothelial proliferation
Cell-based study · Primary human umbilical vein endothelial cells (HUVEC) [1]
The proliferation endpoint was more sensitive under VEGF stimulation than under FBS stimulation.
Literature-Reported Treatment Conditions
- Exposure duration
- 72 h drug exposure
- Method
- Sulforhodamine B proliferation assay; vehicle control and sunitinib comparator
- Vehicle
- DMSO stock; final percentage not specified
- Co-treatment
- 20 ng/mL VEGF or 20% FBS as stimulus
- Reported limits
- Exact drug dilution series and replicate n for this panel are not specified; IC50 values are reported in Results.
Methods and source locations
Compound reported in the paper: Apatinib mesylate; Compound label in the paper: YN968D1
Published material and model only; no verification of the A11407 lot or salt conversion.
Figure 3A and caption; Methods: Cell proliferation assays; Results: Inhibition of proliferation, migration and tube formation of HUVEC
HUVEC proliferation under the indicated stimulus: Sulforhodamine B, 72 h — Results: Inhibition of proliferation, migration and tube formation; Figure 3A; Cell proliferation assays
No detected apoptosis increase in primary mesothelioma cells
Cell-based study · Primary epithelioid malignant peritoneal mesothelioma cells derived from one patient via xenograft [2]
DAPI morphology and caspase assays did not detect an apoptosis increase under the tested conditions.
Literature-Reported Treatment Conditions
- Treatment concentration
- DAPI: 50 μM; caspase: 1, 2, 4, 8, 16, 32 and 64 μM
- Exposure duration
- 24 h
- Method
- DAPI nuclear morphology; Caspase-Glo 3/7 luminescence
- Vehicle
- DMSO stock; final fraction not specified
- Reported limits
- Figure 3D labels blank, negative and positive controls, but control identities are not specified in the apoptosis methods. Exact assay-specific replicate n is not given; general Methods states at least three repeats.
Methods and source locations
Compound reported in the paper: Apatinib mesylate; Compound label in the paper: apatinib
Published material and model only; no verification of the A11407 lot or salt conversion.
Methods: Apoptosis Assays; Results: Apatinib Does Not Induce Apoptosis of MPM Cells; Figure 3C–D
Apoptotic morphology and caspase activity: DAPI and Caspase-Glo 3/7; Methods calls the latter a caspase-3 assay — Figure 3C–D; Results: Apatinib Does Not Induce Apoptosis of MPM Cells